ERBB2 and neoplasm: To evaluate the associations between HER2 expression and immunotherapy‐related features, we compared the PD‐L1 CPS, TMB level,27, 28 MSI status,29 and mutant‐allele tumor heterogeneity (MATH)30 between HER2+ and HER2− subgroups.